Standard
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers. / Talwelkar, Sarang S.; Nagaraj, Ashwini S.; Devlin, Jennifer R.; Hemmes, Annabrita; Potdar, Swapnil; Kiss, Elina A.; Saharinen, Pipsa; Salmenkivi, Kaisa; Mäyränpää, Mikko I.; Wennerberg, Krister; Verschuren, Emmy W.
In:
Molecular Cancer Therapeutics, Vol. 18, No. 10, 2019, p. 1863-1874.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Talwelkar, SS, Nagaraj, AS, Devlin, JR, Hemmes, A, Potdar, S, Kiss, EA, Saharinen, P, Salmenkivi, K, Mäyränpää, MI
, Wennerberg, K & Verschuren, EW 2019, '
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers',
Molecular Cancer Therapeutics, vol. 18, no. 10, pp. 1863-1874.
https://doi.org/10.1158/1535-7163.MCT-18-0573APA
Talwelkar, S. S., Nagaraj, A. S., Devlin, J. R., Hemmes, A., Potdar, S., Kiss, E. A., Saharinen, P., Salmenkivi, K., Mäyränpää, M. I.
, Wennerberg, K., & Verschuren, E. W. (2019).
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers.
Molecular Cancer Therapeutics,
18(10), 1863-1874.
https://doi.org/10.1158/1535-7163.MCT-18-0573Vancouver
Talwelkar SS, Nagaraj AS, Devlin JR, Hemmes A, Potdar S, Kiss EA et al.
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers.
Molecular Cancer Therapeutics. 2019;18(10):1863-1874.
https://doi.org/10.1158/1535-7163.MCT-18-0573Author
Talwelkar, Sarang S. ; Nagaraj, Ashwini S. ; Devlin, Jennifer R. ; Hemmes, Annabrita ; Potdar, Swapnil ; Kiss, Elina A. ; Saharinen, Pipsa ; Salmenkivi, Kaisa ; Mäyränpää, Mikko I. ; Wennerberg, Krister ; Verschuren, Emmy W. / Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers. In: Molecular Cancer Therapeutics. 2019 ; Vol. 18, No. 10. pp. 1863-1874.
Bibtex
@article{bb89b05017ed45b28811d99b1bbdeded,
title = "Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers",
author = "Talwelkar, {Sarang S.} and Nagaraj, {Ashwini S.} and Devlin, {Jennifer R.} and Annabrita Hemmes and Swapnil Potdar and Kiss, {Elina A.} and Pipsa Saharinen and Kaisa Salmenkivi and M{\"a}yr{\"a}np{\"a}{\"a}, {Mikko I.} and Krister Wennerberg and Verschuren, {Emmy W.}",
year = "2019",
doi = "10.1158/1535-7163.MCT-18-0573",
language = "English",
volume = "18",
pages = "1863--1874",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research (A A C R)",
number = "10",
}
RIS
TY - JOUR
T1 - Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers
AU - Talwelkar, Sarang S.
AU - Nagaraj, Ashwini S.
AU - Devlin, Jennifer R.
AU - Hemmes, Annabrita
AU - Potdar, Swapnil
AU - Kiss, Elina A.
AU - Saharinen, Pipsa
AU - Salmenkivi, Kaisa
AU - Mäyränpää, Mikko I.
AU - Wennerberg, Krister
AU - Verschuren, Emmy W.
PY - 2019
Y1 - 2019
U2 - 10.1158/1535-7163.MCT-18-0573
DO - 10.1158/1535-7163.MCT-18-0573
M3 - Journal article
C2 - 31320402
VL - 18
SP - 1863
EP - 1874
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 10
ER -
